Jasper: New Briquilimab Data Shows Safety, Efficacy In Blood Cancer Patients

 

• Jasper Therapeutics Inc 
  JSPR+25.4%+ Free Alerts
   announced that new data for briquilimab (formerly JSP191) will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place next month.
• The studies demonstrate that a regimen of briquilimab plus Flu/TBI leads to successful engraftment of donor blood stem cell without the usual short and long-term toxicities accompanying alternative busulfan-based regimens commonly used in the transplant of donor or gene-corrected cells. 
• The company says that briquilimab can potently synergize with radiation, amplifying its stem cell-depleting effects without increasing off-target toxicity.
• The first abstract demonstrates that briquilimab was safe, well-tolerated, and achieved durable remissions in 8 of 12 first-treated AML patients. 
• All eight patients were relapse-free at one-year follow-up. Six of 9 patients who entered transplant with detectable AML showed long-term eradication of the AML clones at one-year. 
• In a companion abstract, 29 AML and MDS patients treated with briquilimab and Flu/TBI demonstrated lower-than-expected rates of acute and chronic graft-versus-host disease (GVHD). 

https://www.benzinga.com/general/biotech/23/01/30409391/jasper-therapeutics-trade-higher-as-new-briquilimab-data-shows-safety-efficacy-in-blood-cancer-pa